下游工艺研究员/Research Investigator, Downstream(博士岗)当面告知

百濟神州有限公司
2026-12-30 19:40:45
校招博士27届

岗位详情

地区:

上海

专业要求:

化学生物技术生物工程药学化学工程

岗位职责:

General Description: Downstream process development is a critical function of biologics CMC activities. The goal of downstream process is to develop a set of purification procedures, which can capture, purify targeted drug API from cell culture broth and finally get drug substance. The purification procedure will utilize various bioseperation technology including different chromatography, membrance seperation, UF/DF and some specific skills, such as viral clearance. The process development work also involves scale up, tech transfer to commerical and support GMP manufacturing. It will offer knowledge and understanding of large molecule CMC work, Biochemical Engineering, GMP manufacturing, life cycle of drug and other speical skill, e.g. project management, etc. Job Description (including but not limited to): 1) Support early-stage and late phase biological product development. Responsible for antibody purification process development and ADC process development, tox material preparation, tech transfer, downstream process optimization and characterization. 2) As function representative, working closely with stakeholders (technical development functions, Research, CMC, Quality, MST/manufacture, Reg CMC, clinical operation, etc.) to advance technical development of newly NMEs according to aligned development timeline. Enable IND/BLA submission per aligned CMC timeline. 3) Key contributor to relevant CMC sections in IND/BLA submission. 4) Provide solution/insights on technical issues from biologics developability assessment to CMC development. 5) Stay current with emerging trends, new technology POC aiming for cost effectiveness and/or improving operation excellence and efficiency. 6) Junior team members training and lab management. Qualification: 1) PhD in chemistry, chemical engineering, pharmaceutical sciences, biochemistry, biotechnology, bioengineering, or relevant field. 2) Proficient experimental skills, capable of independently completing study design, experiment execution, data collection and analysis, as well as report writing, and able to troubleshoot abnormal experimental results. 3) Familiar with antibody purification and ADC conjugation principles and operations, e.g., chromatography, UF/DF, stochastic conjugation and site-specific conjugation, etc. 4) High self-motivation to solve problems and explore state-of-the-art technologies. 5) Good English proficiency (reading/writing/speaking) for technical communication, documentation and cross-functional collaboration. 6) Ability to work independently, identify, and solve problems. Strong interpersonal skills with a good collaboration spirit. Result-driven with high agility in a changing environment. 7) Experience in applying AI tools to improve real work outcomes, with clear examples of impact (quality, speed, decision support) is a plus.

招聘要求:

General Description: Downstream process development is a critical function of biologics CMC activities. The goal of downstream process is to develop a set of purification procedures, which can capture, purify targeted drug API from cell culture broth and finally get drug substance. The purification procedure will utilize various bioseperation technology including different chromatography, membrance seperation, UF/DF and some specific skills, such as viral clearance. The process development work also involves scale up, tech transfer to commerical and support GMP manufacturing. It will offer knowledge and understanding of large molecule CMC work, Biochemical Engineering, GMP manufacturing, life cycle of drug and other speical skill, e.g. project management, etc. Job Description (including but not limited to): 1) Support early-stage and late phase biological product development. Responsible for antibody purification process development and ADC process development, tox material preparation, tech transfer, downstream process optimization and characterization. 2) As function representative, working closely with stakeholders (technical development functions, Research, CMC, Quality, MST/manufacture, Reg CMC, clinical operation, etc.) to advance technical development of newly NMEs according to aligned development timeline. Enable IND/BLA submission per aligned CMC timeline. 3) Key contributor to relevant CMC sections in IND/BLA submission. 4) Provide solution/insights on technical issues from biologics developability assessment to CMC development. 5) Stay current with emerging trends, new technology POC aiming for cost effectiveness and/or improving operation excellence and efficiency. 6) Junior team members training and lab management. Qualification: 1) PhD in chemistry, chemical engineering, pharmaceutical sciences, biochemistry, biotechnology, bioengineering, or relevant field. 2) Proficient experimental skills, capable of independently completing study design, experiment execution, data collection and analysis, as well as report writing, and able to troubleshoot abnormal experimental results. 3) Familiar with antibody purification and ADC conjugation principles and operations, e.g., chromatography, UF/DF, stochastic conjugation and site-specific conjugation, etc. 4) High self-motivation to solve problems and explore state-of-the-art technologies. 5) Good English proficiency (reading/writing/speaking) for technical communication, documentation and cross-functional collaboration. 6) Ability to work independently, identify, and solve problems. Strong interpersonal skills with a good collaboration spirit. Result-driven with high agility in a changing environment. 7) Experience in applying AI tools to improve real work outcomes, with clear examples of impact (quality, speed, decision support) is a plus.

公司介绍

百濟神州有限公司

百濟神州有限公司

百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资

百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。